PTG-100

April 2, 2018April 2, 2018

Protagonist Halts Clinical Trial of PTG-100 for UC After Analysis Finds Study Futile

News

A Phase 2b trial of PTG-100, an investigative therapy for moderate-to-severe ulcerative colitis (UC), has been discontinued after an interim analysis deemed the study futile, according to Protagonist Therapeutics. The randomized, ... Read more

January 12, 2018

Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein

News

Protagonist Therapeutics has obtained a U.S. patent for an inflammatory bowel disease treatment that is in clinical trials. PTG-100 inhibits a protein known as alpha-4-beta-7 integrin that is associated with IBDs. Scientists consider it one ... Read more

May 4, 2017

Protagonist to Present Preclinical Findings on PTG-200 for Crohn’s Disease at Conference

News

Protagonist Therapeutics will present preclinical research data on its investigational drug PTG-200 as a potential treatment for Crohn’s disease. The findings will be presented May 6 at the Digestive Disease Week conference ... Read more

January 19, 2017

Protagonist Therapeutics Begins Phase 2b Trial of PTG-100 as Ulcerative Colitis Treatment

News

Protagonist Therapeutics has started a Phase 2b clinical trial to evaluate PTG-100, its lead candidate as a potential treatment for ulcerative colitis (UC). The multicenter, randomized, double-blind, placebo-controlled, parallel, adaptive two-stage trial ... Read more

July 20, 2015July 20, 2015

Protagonist Therapeutics Raises $40 MillionTo Advance IBD Oral Therapy Development

IBD News, News

Protagonist Therapeutics, Inc., a company that specializes in advancing novel, orally-stable peptide treatments for gastrointestinal diseases and disorders, has just closed a $40 million Series C financing. The investment will fund continued ... Read more